BCA
ENTA icon

Berman Capital Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Berman Capital Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3K Sell
64
-49
-43% -$2.42K ﹤0.01% 1575
2021
Q2 		$4K Buy
113
+29
+35% +$1.42K ﹤0.01% 1396
2021
Q1 		$4K Buy
84
+32
+62% +$1.6K ﹤0.01% 1326
2020
Q4 		$2K Sell
52
-89
-63% -$3.92K ﹤0.01% 1395
2020
Q3 		$6K Buy
+141
New +$6.83K ﹤0.01% 960

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Berman Capital Advisors's ENTA Position: Q3 2021 in Review

Berman Capital Advisors reduced its Enanta Pharmaceuticals (ENTA) stake by 43% in Q3 2021, selling an estimated $2.42K and leaving 64 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

Berman Capital Advisors first reported a position in ENTA in Q3 2020 and has held it in 5 quarters since. The position peaked at $6K in Q3 2020. 148 funds tracked by Wall St. Rank hold ENTA as of Q3 2021.

  • Berman Capital Advisors held 64 shares of Enanta Pharmaceuticals worth $3K as of Q3 2021.
  • Berman Capital Advisors sold 49 Enanta Pharmaceuticals shares in Q3 2021, an estimated $2.42K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1575 holding.
  • Berman Capital Advisors first reported a position in Enanta Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
  • Berman Capital Advisors's Enanta Pharmaceuticals position peaked at $6K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.